ORDER A TEST Log In Contact Us

Tempus IO™

A comprehensive immunotherapy platform that provides sophisticated specimen analysis and data products, enabling biopharma partners to assess key aspects of the tumor microenvironment (TME).

Tempus’ integrated approach to immunotherapy

Tempus innovates within the fast-moving field of immunotherapy to provide actionable and cutting-edge services for pharma partners advancing IO therapies, including ADCx, TCR cell therapies, and immune checkpoint inhibitors (ICI).

Our product offerings

Leverage Tempus’ suite of IO data to understand the tumor microenvironment, included with applicable assay orders.

Download the Tempus IO Overview to learn more

  • Tempus xT: Solid Tumor DNA Seq

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    HLA Loss of Heterozygosity (LOH)

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

  • Tempus xE: Whole Exome

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

  • Tempus xR: Whole Transcriptome RNA Seq

    Gene Expression Target Profiling3

    Neoantigen Prediction

    Immune Infiltration

    Oncogenic Virus

    T-cell Receptor / B-cell Receptor Repertoire

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

  • Tempus xF/xF+: Liquid Biopsies

    Blood Tumor Mutational Burden (bTMB) (xF+ only)

    Microsatellite Instability (MSI) high status (xF/xF+)

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

HLA Loss of Heterozygosity (LOH)

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Gene Expression Target Profiling3

Neoantigen Prediction

Immune Infiltration

Oncogenic Virus

T-cell Receptor / B-cell Receptor Repertoire

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Blood Tumor Mutational Burden (bTMB) (xF+ only)

Microsatellite Instability (MSI) high status (xF/xF+)

Tempus IO goes beyond sequencing

Tempus’ analytical capabilities enhance sequencing data, offering the opportunity to identify potential biomarkers correlating with therapy response. Supplementary data and custom analyses are available as add-ons to meet your specific needs.4

Powering clinical development with data and technology

We operate CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is completed within 8–10 days on average of receiving samples.

Download our lab overview
image description

Our Science

A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database

In a pan-cancer analysis, significant differences in tumor immune states were observed by primary and metastatic sites, and by indication, with important implications for IO-treatment strategies. These data provide valuable and timely insights for IO research, where simultaneous assessment of molecular, immune, and clinical traits is required.

Learn more

Associations between multimodal immune biomarkers and clinical outcomes in a real-world non-small cell lung cancer cohort

Here we demonstrate that RNA-based immune signatures are significantly associated with clinical benefit and may supplement well-established ICI biomarkers in therapy selection. These immune RNA-based signatures need to be prospectively validated in future studies.

Learn more

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Learn how HLA LOH can be reliably detected using the Tempus xT next‑generation sequencing (NGS) assay.

Learn more
  1. Assessment of MMR proteins by IHC, including MLH1, MSH2, MSH6, and PMS2, as well as PD-L1 IHC, is available as an optional add-on for Tempus xT/xE orders. This service is not automatically included in every order and should be selected by the customer.
  2. Tempus provides information on multiple variants and features that have been reported to confer resistance to immunotherapy. This includes mutations and/or copy number alterations in immune-associated genes that affect antigen presentation or interferon signaling. (xT, xE only)
  3. Tempus performs RNA whole transcriptome sequencing when sufficient tissue samples are provided.
  4. The availability of supplementary data is dependent on the scope of the request.

Partner with us

With a broad range of laboratory services and data analysis that support immunotherapy development, Tempus has the solutions you need.